Up to date, expert answers to frequently asked questions (FAQ) about oxygen supply systems, respiratory care and pulse oximetry written by OCC & collaborators.
Can test-to-treat be applied to COVID-19 patients without advanced age or other risk factors?
- Most of the available evidence comes from studies in populations with risk factors for progression to severe disease, including advanced age. In this population, the benefit is clear.
- There is less data on the use of Paxlovid (nirmatrelvir/ritonavir) in patients without risk factors (including age). Healthier patients may have less benefit, as their risk of severe disease is lower to begin with.
- For now, the risk-benefit ratio is only well established in those with risk factors including advanced age.